Subtype of EGFR exon 19 deletion mutations

Nobukazu Fujimoto

DOI: https://doi.org/10.21037/tlcr-23-680

2024-01-31

Translational Lung Cancer Research

Abstract:Nobukazu Fujimoto ^ Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan ^ ORCID: 0000-0002-4516-0433. Comment on: Grant MJ, Aredo JV, Starrett JH, et al . Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clin Cancer Res 2023;29:2123-30. Keywords: Epidermal growth factor receptor mutation ( EGFR mutation); exon 19 deletion; uncommon mutation; anti-angiogenic agent; next-generation genome sequencing (NGS) Submitted Oct 23, 2023. Accepted for publication Dec 19, 2023. Published online Jan 17, 2024. doi: 10.21037/tlcr-23-680 Epidermal growth factor receptor ( EGFR ) mutations in non-small cell lung cancer (NSCLC) are associated with favorable clinical response to EGFR tyrosine kinase inhibitors (TKIs). There are several EGFR-TKIs approved in the US, Japan, and other countries for the treatment of NSCLC with EGFR mutation. The first-generation EGFR-TKIs, gefitinib and erlotinib, bind reversibly to the Adenosine tri-phosphate-binding pockets of the receptor, whereas the second-generation TKIs, afatinib and dacomitinib additionally react covalently with the side-chain of cysteine 797 in EGFR (1). A third-generation TKI osimertinib has been shown to improve progression-free survival (PFS) (2) and overall survival (OS) (3) compared to the first-generation EGFR-TKIs in the first-line setting, and also been shown to be effective in the second-line treatment for patients with EGFR p.T790M mutation (4). There are two common EGFR mutations; one is in-frame deletions in exon 19 (19Del) and the other is a point mutation in exon 21 (p.L858R), which account for approximately 90% of all alterations and are associated with sensitivity to EGFR-TKIs (5). The efficacy of EGFR-TKIs has established for these common mutations, however, few prospective data are available for other uncommon mutations. Uncommon EGFR mutations are highly heterogeneous including p.G719X, p.L861Q, p.S768I, and others (6), and vary widely in terms of their sensitivity to EGFR-TKIs. Afatinib has been applied most for these uncommon mutations possibly because of current availability of data in previous clinical studies, in which patients with uncommon mutations were included (6,7). Recent studies indicate that osimertinib might be active also against certain uncommon EGFR mutations (8,9). However, the optimal treatment strategy for these uncommon EGFR mutations has not been established. Although it is fully established that NSCLCs with 19Del are sensitive to EGFR-TKIs, recent studies revealed that there are some subtypes among 19Del. The most frequently observed 19Del is the elimination of 5 amino acids (E746-A750) between the third β-strand of the EGFR tyrosine kinase domain and its key regulatory αC helix (10). However, several other 19Del mutations have also been demonstrated between amino acids 745 and 753. Many of these deletions are replacement of the deleted amino acids with a non-native residue which start at leucine 747, where proline and serine respectively are introduced, resulted in L747-A750>P and L747-P753>S variants (11). Very little is known about potential differences in sensitivity to EGFR-TKIs among individual 19Dels. The differences in TKI sensitivity among 19Del have begun to emerge from several studies. A recent report of in vitro study suggested that L747-A750>P variant was associated with poor inhibition by erlotinib and osimertinib but was strongly inhibited by afatinib, partly due to structural characteristic of the variant (12). Although there were some different results in different studies, the importance of EGFR-TKI selection specific to each mutation has been highlighted in these studies. Grant et al. recently reported that patients of NSCLC with L747-A750>P variant of 19Del was associated with inferior PFS compared with the main E746-A750 variant when treated with osimertinib as a first-line therapy (13). They performed a multicenter, retrospective cohort study based on an international cancer registry conducted by American Association for Cancer Research that linked next-generation genome sequencing (NGS) data with clinical information of patients treated at 18 contributing institutions (14). In the study, they identified 72 distinct variants of 19Del ranging in frequency from 28.1% of E746-A750 to 0.03% of L747-A750>P, and demonstrated that main E746-A750 was associated with significantly prolonged PFS (median 21.3 months with 95% confidence interval of 17.0–31.7 months) versus L747-A750>P (median 11.7 months with 95% confidence interval of 10.8–29.4, P=0.043) in patients treated with first-line osimertinib. Although there are some limitations in their study, including its retrospective study design and limited numb -Abstract Truncated-

oncology,respiratory system